Abstract
Evidence-based therapies for atherosclerotic cardiovascular disease (ASCVD) prevention that target LDL cholesterol include statins alone or in combination with ezetimibe or inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9). However, these treatments are sometimes only partly effective, or there can be issues with tolerability or accessibility. Furthermore, substantial residual risk of ASCVD remains in many patients treated with statins who attain target LDL cholesterol concentrations. Treatment of other dyslipidaemias such as severe hypertriglyceridemia is also suboptimal with current drug therapies. For these reasons, several drug development programmes are being pursued.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
